84 related articles for article (PubMed ID: 3504722)
41. Influence of bisphosphonates or recombinant human parathyroid hormone on
De Winter DTC; Van Atteveld JE; Buijs-Gladiness JGCAM; Pieters R; Neggers SJCMM; Meijerink JPP; Van den Heuvel-Eibrink MM
Haematologica; 2023 Feb; 108(2):605-609. PubMed ID: 36226491
[No Abstract] [Full Text] [Related]
42. Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.
Kim SB; Lee JS; Kim HT; Im YH; Kim TW; Ryoo BY; Park YH; Park JO; Park K; Katoh H; Yamamoto M
Curr Ther Res Clin Exp; 2007 May; 68(3):193-204. PubMed ID: 24683210
[TBL] [Abstract][Full Text] [Related]
43. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Westin JR; Thompson MA; Cataldo VD; Fayad LE; Fowler N; Fanale MA; Neelapu S; Samaniego F; Romaguera J; Shah J; McLaughlin P; Pro B; Kwak LW; Sanjorjo P; Murphy WA; Jimenez C; Toth B; Dong W; Hagemeister FB
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):99-105. PubMed ID: 23276888
[TBL] [Abstract][Full Text] [Related]
44. Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner.
Recenti R; Leone G; Simi L; Orfei M; Pinzani P; Pieraccini G; Moneti G; Carossino AM; Franchi A; Bartolucci G; Carbonell Sala S; Ginanneschi M; Tanini A; Brandi ML
Clin Cases Miner Bone Metab; 2007 May; 4(2):146-55. PubMed ID: 22461215
[TBL] [Abstract][Full Text] [Related]
45. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions.
Quattrocchi CC; Piciucchi S; Sammarra M; Santini D; Vincenzi B; Tonini G; Grasso RF; Zobel BB
Radiol Med; 2007 Oct; 112(7):1049-59. PubMed ID: 17952675
[TBL] [Abstract][Full Text] [Related]
46. Strategies for management of prostate cancer-related bone pain.
Pelger RC; Soerdjbalie-Maikoe V; Hamdy NA
Drugs Aging; 2001; 18(12):899-911. PubMed ID: 11888345
[TBL] [Abstract][Full Text] [Related]
47. Structural aspects of the effectiveness of bisphosphonates as competitive inhibitors of the plant vacuolar proton-pumping pyrophosphatase.
Gordon-Weeks R; Parmar S; Davies TG; Leigh RA
Biochem J; 1999 Feb; 337 ( Pt 3)(Pt 3):373-7. PubMed ID: 9895279
[TBL] [Abstract][Full Text] [Related]
48. Bisphosphonates and the treatment of bone disease in the elderly.
Johansen A; Stone M; Rawlinson F
Drugs Aging; 1996 Feb; 8(2):113-26. PubMed ID: 8845585
[TBL] [Abstract][Full Text] [Related]
49. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm G; Vloedgraven H; van Beek E; van der Wee-Pals L; Löwik C; Papapoulos S
J Clin Invest; 1996 Aug; 98(3):698-705. PubMed ID: 8698861
[TBL] [Abstract][Full Text] [Related]
50. Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover.
Degrossi OJ; Ortiz M; Degrossi EB; García del Río H; Barreira JC; Messina D; Kerzberg E; Roldán EJ; Montuori E; Pérez Lloret A
Eur J Clin Pharmacol; 1995; 48(6):489-94. PubMed ID: 8582468
[TBL] [Abstract][Full Text] [Related]
51. New bisphosphonates in osteoporosis.
Fleisch H
Osteoporos Int; 1993; 3 Suppl 2():S15-22. PubMed ID: 8481594
[TBL] [Abstract][Full Text] [Related]
52. Bisphosphonates in osteoporosis?
Bijvoet OL; Valkema R; Löwik CW; Papapoulos SE
Osteoporos Int; 1993; 3 Suppl 1():230-6. PubMed ID: 8461570
[No Abstract] [Full Text] [Related]
53. The effects of several diphosphonates on murine bone marrow proliferation.
Richard KA; Staite ND
Agents Actions; 1993; 39 Spec No():C93-5. PubMed ID: 8273598
[TBL] [Abstract][Full Text] [Related]
54. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.
Selander K; Lehenkari P; Väänänen HK
Calcif Tissue Int; 1994 Nov; 55(5):368-75. PubMed ID: 7532540
[TBL] [Abstract][Full Text] [Related]
55. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Coleman RE; Woll PJ; Miles M; Scrivener W; Rubens RD
Br J Cancer; 1988 Nov; 58(5):621-5. PubMed ID: 3219273
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.
Hughes DE; MacDonald BR; Russell RG; Gowen M
J Clin Invest; 1989 Jun; 83(6):1930-5. PubMed ID: 2524504
[TBL] [Abstract][Full Text] [Related]
57. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?
Klenner T; Wingen F; Keppler BK; Krempien B; Schmähl D
J Cancer Res Clin Oncol; 1990; 116(4):341-50. PubMed ID: 2152296
[TBL] [Abstract][Full Text] [Related]
58. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation.
Rawlinson PS; Green RH; Coggins AM; Boyle IT; Gibson BE
Arch Dis Child; 1991 May; 66(5):638-9. PubMed ID: 2039258
[TBL] [Abstract][Full Text] [Related]
59. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
Fleisch H
Drugs; 1991 Dec; 42(6):919-44. PubMed ID: 1724640
[TBL] [Abstract][Full Text] [Related]
60. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
